E Fund Management Co., Ltd. Seagen Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $56,495 - $63,767	295 Added 7.95%	4,008 $850,000
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $35,463 - $38,981	-189 Reduced 4.84%	3,713 $715,000
Q1 2023 May 11, 2023	SELL	$127.59 - $203.08 $162,166 - $258,114	-1,271 Reduced 24.57%	3,902 $790,000
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $30,164 - $35,766	257 Added 5.23%	5,173 $665,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $2,299 - $3,061	17 Added 0.35%	4,916 $673,000
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $132,748 - $218,782	1,220 Added 33.16%	4,899 $867,000
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $87,076 - $114,914	728 Added 24.67%	3,679 $530,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $11,263 - $15,077	79 Added 2.75%	2,951 $456,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $26,495 - $31,586	186 Added 6.92%	2,872 $488,000
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $369,351 - $512,488	2,686 New	2,686 $372,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.